Despite intensive chemotherapy, the overall survival of AML patients is still less than 30% for adults and 60% for children, and most of the patients with MLL-rearranged AML fail to survive longer than 5 years4, 9–11. Here, KMT2A is linked to acute myeloid leukemia.